These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 29691753

  • 21. Development of respirable nanomicelle carriers for delivery of amphotericin B by jet nebulization.
    Gilani K, Moazeni E, Ramezanli T, Amini M, Fazeli MR, Jamalifar H.
    J Pharm Sci; 2011 Jan; 100(1):252-9. PubMed ID: 20602350
    [Abstract] [Full Text] [Related]

  • 22. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
    Fukui H, Koike T, Nakagawa T, Saheki A, Sonoke S, Tomii Y, Seki J.
    Int J Pharm; 2003 Nov 28; 267(1-2):101-12. PubMed ID: 14602388
    [Abstract] [Full Text] [Related]

  • 23. Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans.
    van Etten EW, Chander HR, Snijders SV, Bakker-Woudenberg IA.
    J Antimicrob Chemother; 1995 Dec 28; 36(6):961-74. PubMed ID: 8821595
    [Abstract] [Full Text] [Related]

  • 24. Heat-induced reformulation of amphotericin B-deoxycholate favours drug uptake by the macrophage-like cell line J774.
    Chéron M, Petit C, Bolard J, Gaboriau F.
    J Antimicrob Chemother; 2003 Dec 28; 52(6):904-10. PubMed ID: 14613963
    [Abstract] [Full Text] [Related]

  • 25. Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation.
    Alvarez C, Andes DR, Kang JY, Krug C, Kwon GS.
    Pharm Res; 2017 May 28; 34(5):1115-1124. PubMed ID: 28205003
    [Abstract] [Full Text] [Related]

  • 26. Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation.
    Hussain A, Samad A, Singh SK, Ahsan MN, Haque MW, Faruk A, Ahmed FJ.
    Drug Deliv; 2016 May 28; 23(2):642-47. PubMed ID: 25013957
    [Abstract] [Full Text] [Related]

  • 27. A novel formulation of solubilised amphotericin B designed for ophthalmic use.
    Serrano DR, Ruiz-Saldaña HK, Molero G, Ballesteros MP, Torrado JJ.
    Int J Pharm; 2012 Nov 01; 437(1-2):80-2. PubMed ID: 22890190
    [Abstract] [Full Text] [Related]

  • 28. Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.
    Zia Q, Khan AA, Swaleha Z, Owais M.
    Int J Nanomedicine; 2015 Nov 01; 10():1769-90. PubMed ID: 25784804
    [Abstract] [Full Text] [Related]

  • 29. Amphotericin B-copper(II) complex as a potential agent with higher antifungal activity against Candida albicans.
    Chudzik B, Tracz IB, Czernel G, Fiołka MJ, Borsuk G, Gagoś M.
    Eur J Pharm Sci; 2013 Aug 16; 49(5):850-7. PubMed ID: 23791641
    [Abstract] [Full Text] [Related]

  • 30. Biochemical characterization of GM1 micelles-Amphotericin B interaction.
    Leonhard V, Alasino RV, Bianco ID, Garro AG, Heredia V, Beltramo DM.
    Curr Drug Deliv; 2015 Aug 16; 12(4):406-14. PubMed ID: 25772153
    [Abstract] [Full Text] [Related]

  • 31. Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves.
    Ralph ED, Khazindar AM, Barber KR, Grant CW.
    Antimicrob Agents Chemother; 1991 Jan 16; 35(1):188-91. PubMed ID: 2014976
    [Abstract] [Full Text] [Related]

  • 32. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system.
    Tabosa Do Egito ES, Appel M, Fessi H, Barratt G, Puisieux F, Devissaguet JP.
    J Antimicrob Chemother; 1996 Sep 16; 38(3):485-97. PubMed ID: 8889723
    [Abstract] [Full Text] [Related]

  • 33. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
    Lewis RE, Wiederhold NP, Prince RA, Kontoyiannis DP.
    J Antimicrob Chemother; 2006 Feb 16; 57(2):288-93. PubMed ID: 16387749
    [Abstract] [Full Text] [Related]

  • 34. Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral Candida albicans.
    Zhou L, Zhang P, Chen Z, Cai S, Jing T, Fan H, Mo F, Zhang J, Lin R.
    Int J Nanomedicine; 2017 Feb 16; 12():4269-4283. PubMed ID: 28652732
    [Abstract] [Full Text] [Related]

  • 35. In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating.
    Petit C, Chéron M, Joly V, Rodrigues JM, Bolard J, Gaboriau F.
    J Antimicrob Chemother; 1998 Dec 16; 42(6):779-85. PubMed ID: 10052902
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Antifungal Activity of Chitosan-Coated Poly(lactic-co-glycolic) Acid Nanoparticles Containing Amphotericin B.
    Ludwig DB, de Camargo LEA, Khalil NM, Auler ME, Mainardes RM.
    Mycopathologia; 2018 Aug 16; 183(4):659-668. PubMed ID: 29497926
    [Abstract] [Full Text] [Related]

  • 39. Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo.
    Tang X, Zhu H, Sun L, Hou W, Cai S, Zhang R, Liu F.
    Int J Nanomedicine; 2014 Aug 16; 9():5403-13. PubMed ID: 25473279
    [Abstract] [Full Text] [Related]

  • 40. Ascorbyl dipalmitate/PEG-lipid nanoparticles as a novel carrier for hydrophobic drugs.
    Moribe K, Maruyama S, Inoue Y, Suzuki T, Fukami T, Tomono K, Higashi K, Tozuka Y, Yamamoto K.
    Int J Pharm; 2010 Mar 15; 387(1-2):236-43. PubMed ID: 20005934
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.